Analysis of genetic and clinical characteristics of PMP22-associated peripheral neuropathy

doi:10.3969/j.issn.1674-8115.2022.05.008

Abstract

Abstract: Objective

·To investigate the genetic and clinical features of peripheral neuropathy patients with PMP22 gene variations and the association between genotype and clinical phenotype.

Methods

·A total of 162 patients with peripheral neuropathy who were treated in Department of Neurology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine from 2006 to 2022 were collected. Molecular detecting techniques including combining multiplex ligation-dependent probe amplification (MLPA), whole exon sequencing (WES) and Sanger sequencing were used to comprehensively analyze the genetic variation of 162 patients, and 26 probands with PMP22 gene variations and their 33 family members were screened out. The genetic variations included duplication, deletion and point mutations. The clinical and genetic characteristics of 26 patients with PMP22-associated peripheral neuropathy were further analyzed. The clinical characteristics included clinical demographic data, clinical manifestations, electrophysiological and pathological characteristics.

Results

·There were a total of 59 (37 male and 22 female) individuals with PMP22-associated peripheral neuropathy, among whom 46 patients in 13 families had positive family histories and 13 did not. The median age at onset of neuropathy was 34.0 (14.0, 49.5) years old. The initial symptom was limb weakness or limb numbness. There were 51 Charcot-Marie-Tooth type-1A (CMT1A) patients with PMP22 duplication, 6 hereditary neuropathy with liability to pressure palsies (HNPP) patients with PMP22 deletion and 2 Dejerine-Sottas syndrome (DSS) patients with PMP22 point mutations (p.S72L and p.G100V). Sixteen patients underwent electrophysiological detections. Compared with the 4 PMP22 deletion patients, the motor nerve conduction velocity (MCV), compound muscle action potential (CMAP) and sensory nerve conduction velocities (SCV) of 12 PMP22 duplication patients were obviously decreased (all P<0.05). Conduction block was found in both kinds of mutation types. Sural nerve biopsies were performed in 12 patients, including 8 PMP22 duplication, 3 PMP22 deletion and 1 PMP22 point mutation, and pathological changes such as thinning of myelinated nerve fibers, “onion bulbs” and decreased nerve fiber density were observed in varying degrees.

Conclusion

·PMP22 gene-associated neuropathies can be characterized by CMT1A, HNPP and DSS with high clinical heterogeneity. Patients with demyelinating manifestations on electrophysiological detections and sural nerve biopsy need genetic testing for PMP22 gene duplication, deletion and point mutation after ruling out acquired etiology. It is available to help optimize diagnosis and genetic counseling of the disease.

Key words: Charcot-Marie-Tooth type-1A (CMT1A), hereditary neuropathy with liability to pressure palsies (HNPP), Dejerine-Sottas syndrome (DSS), PMP22 gene, mutation

CLC Number:

R745.4⁺9

ZHU Xiaowei, ZHAN Feixia, ZHANG Chao, LIU Shihua, ZHONG Ping, CAO Li, LUAN Xinghua. Analysis of genetic and clinical characteristics of PMP22-associated peripheral neuropathy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 609-616.

Figures/Tables 4

TrendMD

References 35

1	PANTERA H, MORAN J J, HUNG H A, et al. Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer[J]. Hum Mol Genet, 2018, 27(16): 2830-2839.
2	LIU X X, DUAN X H, ZHANG Y S, et al. Clinical and genetic diversity of PMP22 mutations in a large cohort of Chinese patients with Charcot-Marie-tooth disease[J]. Front Neurol, 2020, 11: 630.
3	朱啸巍, 钟平, 栾兴华. PMP22相关性周围神经病的临床及遗传学特点[J]. 中国实用神经疾病杂志, 2021, 24(14): 1265-1270.
	ZHU X W, ZHONG P, LUAN X H. The clinical and genetic characteristics of PMP22-associated peripheral neuropathy[J]. Chin J Pract Nerv Dis, 2021, 24(14): 1265-1270.
4	GENTILE L, RUSSO M, FABRIZI G M, et al. Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center[J]. Neurol Sci, 2020, 41(5): 1239-1243.
5	WATILA M M, BALARABE S A. Molecular and clinical features of inherited neuropathies due to PMP22 duplication[J]. J Neurol Sci, 2015, 355(1/2): 18-24.
6	IVANOVIC V, BRANKOVIC M, BJELICA B, et al. Yield of the PMP22 deletion analysis in patients with compression neuropathies[J]. J Neurol, 2020, 267(12): 3617-3623.
7	D'ARRIGO S, TESSAROLLO V, TARONI F, et al. A case of severe early-onset neuropathy caused by a compound heterozygous deletion of the PMP22 gene: clinical and neurographic aspects[J]. Neuropediatrics, 2020, 51(3): 173-177.
8	MORINI A, MALAGUTI M C, MARANGONI S, et al. Neuropathic tremor in chronic inflammatory demyelinating polyneuropathy: the acquired equivalent of the roussy-levy syndrome[J]. Mov Disord Clin Pract, 2015, 3(2): 173-175.
9	徐佳露, 章毅, 赵聪颖, 等. 13例早发型腓骨肌萎缩症的基因分型研究[J]. 中国当代儿科杂志, 2019, 21(7): 670-675.
	XU J L, ZHANG Y, ZHAO C Y, et al. A genotyping study of 13 cases of early-onset Charcot-Marie-Tooth disease[J]. Chin J Contemp Pediat, 2019, 21(7): 670-675.
10	ROA B B, DYCK P J, MARKS H G, et al. Dejerine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene[J]. Nat Genet, 1993, 5(3): 269-273.
11	MARQUES W Jr, THOMAS P K, SWEENEY M G, et al. Dejerine-Sottas neuropathy and PMP22 point mutations: a new base pair substitution and a possible “hot spot” on Ser72[J]. Ann Neurol, 1998, 43(5): 680-683.
12	RUSSO M, LAURÁ M, POLKE J M, et al. Variable phenotypes are associated with PMP22 missense mutations[J]. Neuromuscul Disord, 2011, 21(2): 106-114.
13	RICHARDS S, AZIZ N, BALE S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
14	WU R, LV H, ZHANG W, et al. Clinical and pathological variation of Charcot-Marie-tooth 1A in a large Chinese cohort[J]. Biomed Res Int, 2017, 2017: 6481367.
15	LOUSA M, VÁZQUEZ-HUARTE-MENDICOA C, GUTIÉRREZ A J, et al. Genetic epidemiology, demographic, and clinical characteristics of Charcot-Marie-tooth disease in the island of Gran Canaria (Spain)[J]. J Peripher Nerv Syst, 2019, 24(1): 131-138.
16	BROŽKOVÁ D, MAZANEC R, RYCHLÝ Z, et al. Four novel point mutations in the PMP22 gene with phenotypes of HNPP and Dejerine-Sottas neuropathy[J]. Muscle Nerve, 2011, 44(5): 819-822.
17	AZEVEDO H, PUPE C, PEREIRA R, et al. Pain in Charcot-Marie-Tooth disease: an update[J]. Arq Neuropsiquiatr, 2018, 76(4): 273-276.
18	KAWARAI T, YAMAZAKI H, MIYAMOTO R, et al. PMP22-related disease: a novel splice site acceptor variant and intrafamilial phenotype variability[J]. Neuromuscul Disord, 2019, 29(6): 422-426.
19	MITTENDORF K F, MARINKO J T, HAMPTON C M, et al. Peripheral myelin protein 22 alters membrane architecture[J]. Sci Adv, 2017, 3(7): e1700220.
20	ZHOU Y, MILES J R, TAVORI H, et al. PMP22 regulates cholesterol trafficking and ABCA1-mediated cholesterol efflux[J]. J Neurosci, 2019, 39(27): 5404-5418.
21	SVAREN J, MORAN J J, WU X Y, et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies[J]. Ann Neurol, 2019, 85(6): 887-898.
22	PANTERA H, SHY M E, SVAREN J. Regulating PMP22 expression as a dosage sensitive neuropathy gene[J]. Brain Res, 2020, 1726: 146491.
23	LI J. Genetic factors for nerve susceptibility to injuries: lessons from PMP22 deficiency[J]. Neural Regen Res, 2014, 9(18): 1661-1664.
24	TYSON J, ELLIS D, FAIRBROTHER U, et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome[J]. Brain, 1997, 120 ( Pt 1): 47-63.
25	NELIS E, HAITES N, VAN BROECKHOVEN C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies[J]. Hum Mutat, 1999, 13(1): 11-28.
26	WU R, FU J, MENG L C, et al. Homozygous splice-site mutation c.78+5G>A in PMP22 causes congenital hypomyelinating neuropathy[J]. Neuropathology, 2019, 39(6): 441-446.
27	LIAO Y C, TSAI P C, LIN T S, et al. Clinical and molecular characterization of PMP22 point mutations in Taiwanese patients with inherited neuropathy[J]. Sci Rep, 2017, 7(1): 15363.
28	RAMCHANDREN S. Charcot-Marie-tooth disease and other genetic polyneuropathies[J]. Continuum (Minneap Minn), 2017, 23(5, Peripheral Nerve and Motor Neuron Disorders): 1360-1377.
29	NAGAPPA M, SHARMA S, GOVINDARAJ P, et al. PMP22 gene-associated neuropathies: phenotypic spectrum in a cohort from India[J]. J Mol Neurosci, 2020, 70(5): 778-789.
30	ABE A, NAKAMURA K, KATO M, et al. Compound heterozygous PMP22 deletion mutations causing severe Charcot-Marie-Tooth disease type 1[J]. J Hum Genet, 2010, 55(11): 771-773.
31	AGOSTONI E, GOBESSI S, BRANCOLINI C, et al. Identification and characterization of a new member of the gas3/PMP22 gene family in C. elegans[J]. Gene, 1999, 234(2): 267-274.
32	ABE K T, LINO A M M, HIRATA M T A, et al. A novel stop codon mutation in the PMP22 gene associated with a variable phenotype[J]. Neuromuscul Disord, 2004, 14(5): 313-320.
33	TRACY J A, DYCK P J, KLEIN C J, et al. Onion-bulb patterns predict acquired or inherited demyelinating polyneuropathy[J]. Muscle Nerve, 2019, 59(6): 665-670.
34	MOSS K R, BOPP T S, JOHNSON A E, et al. New evidence for secondary axonal degeneration in demyelinating neuropathies[J]. Neurosci Lett, 2021, 744: 135595.
35	ZHAO H T, DAMLE S, IKEDA-LEE K, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models[J]. J Clin Invest, 2018, 128(1): 359-368.

Index	PMP22 duplication （n=12）		P value^①	PMP22 deletion （n=4）		P value^①	P value^②
Index	Left	Right	P value^①	Left	Right	P value^①	P value^②
CMAP/mV
Median nerve （wrist-APB）	3.401±1.559	3.434±1.886	0.972	6.100±2.823	7.275±1.227	0.553	0.008
Median nerve （elbow-wrist）	2.803±1.509	2.849±1.715	0.959	6.100±3.122	6.850±2.585	0.724	0.006
Ulnar nerve （wrist-ADM）	2.002±1.065	1.828±1.117	0.789	6.400±2.203	7.000±2.483	0.730	0.000
Ulnar nerve （below elbow-wrist）	1.487±1.087	1.243±0.951	0.688	6.075±2.095	6.475±2.294	0.805	0.000
Tibial nerve （ankle-AH）	16.375±1.576	16.775±3.163	0.661	39.033±0.850	37.533±2.774	0.421	0.000
Common peroneal nerve （ankle-EDB）	0.200±0.257	0.223±0.473	0.918	3.023±1.583	3.290±2.532	0.864	0.004
MCV/（m·s^-1）
Median nerve	18.943±3.114	18.529±4.095	0.835	49.65±3.074	50.525±2.344	0.765	0.000
Ulnar nerve	17.833±2.420	18.767±3.266	0.586	50.900±4.809	50.675±8.207	0.964	0.000
Tibial nerve	0.315±0.574	0.343±0.346	0.920	7.533±2.937	8.633±2.754	0.661	0.001
Common peroneal nerve	14.143±3.629	17.100±4.964	0.227	36.775±2.136	35.425±4.751	0.623	0.000
SCV/（m·s^-1）
Median nerve	12.843 （0.000， 310.200）	8.210 （0.000， 33.600）	0.548	41.575±2.990	41.475±2.666	0.962	0.000
Ulnar nerve	12.580 （0.000， 32.700）	9.060 （0.000， 39.300）	0.575	42.450±4.211	43.350±4.807	0.788	0.000
Sural nerve	9.691 （0.000， 34.600）	7.792 （0.000， 27.600）	0.717	40.850±8.009	41.575±7.374	0.898	0.000

Index	PMP22 duplication （n=12）		P value^①	PMP22 deletion （n=4）		P value^①	P value^②
Index	Left	Right	P value^①	Left	Right	P value^①	P value^②
CMAP/mV
Median nerve （wrist-APB）	3.401±1.559	3.434±1.886	0.972	6.100±2.823	7.275±1.227	0.553	0.008
Median nerve （elbow-wrist）	2.803±1.509	2.849±1.715	0.959	6.100±3.122	6.850±2.585	0.724	0.006
Ulnar nerve （wrist-ADM）	2.002±1.065	1.828±1.117	0.789	6.400±2.203	7.000±2.483	0.730	0.000
Ulnar nerve （below elbow-wrist）	1.487±1.087	1.243±0.951	0.688	6.075±2.095	6.475±2.294	0.805	0.000
Tibial nerve （ankle-AH）	16.375±1.576	16.775±3.163	0.661	39.033±0.850	37.533±2.774	0.421	0.000
Common peroneal nerve （ankle-EDB）	0.200±0.257	0.223±0.473	0.918	3.023±1.583	3.290±2.532	0.864	0.004
MCV/（m·s^-1）
Median nerve	18.943±3.114	18.529±4.095	0.835	49.65±3.074	50.525±2.344	0.765	0.000
Ulnar nerve	17.833±2.420	18.767±3.266	0.586	50.900±4.809	50.675±8.207	0.964	0.000
Tibial nerve	0.315±0.574	0.343±0.346	0.920	7.533±2.937	8.633±2.754	0.661	0.001
Common peroneal nerve	14.143±3.629	17.100±4.964	0.227	36.775±2.136	35.425±4.751	0.623	0.000
SCV/（m·s^-1）
Median nerve	12.843 （0.000， 310.200）	8.210 （0.000， 33.600）	0.548	41.575±2.990	41.475±2.666	0.962	0.000
Ulnar nerve	12.580 （0.000， 32.700）	9.060 （0.000， 39.300）	0.575	42.450±4.211	43.350±4.807	0.788	0.000
Sural nerve	9.691 （0.000， 34.600）	7.792 （0.000， 27.600）	0.717	40.850±8.009	41.575±7.374	0.898	0.000

[1]	HE Jiayin, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, QIAN Ying, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of patients with adrenal diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1194-1201.
[2]	CHEN Siyuan, SHI Qing, FU Di, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of diffuse large B-cell lymphoma with lung involvement [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1214-1220.
[3]	JIANG Yi, HUANG Chenhao, LI Zhiliang, WU Junwei, ZHAO Ren, ZHANG Tao. Effect of preoperative chemotherapy combined with immunotherapy in a colorectal cancer patient with KRAS mutation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1256-1260.
[4]	WANG Gaoming, CUI Ran, LI Yanjing, LIU Yingbin. Study on the mechanism of KRAS R68G secondary mutation-induced resistance to KRAS^G12D-targeted inhibitor MRTX1133 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(6): 705-716.
[5]	ZHANG Lanlan, HAN Xu, LI Niu, WANG Jian, LI Shuyuan. Detection efficacy of non-invasive prenatal testing for copy number variations in the recurrent 17p12 region [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(3): 310-316.
[6]	WANG Boen, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(9): 1162-1168.
[7]	GAO Kexing, LIAO Chunhua, LI Shengze, MA Shuangyu, HUANG Lei. Functional site analysis of mucin 1 in regulating the malignant characteristics of tumor cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(11): 1370-1382.
[8]	ZHAN Tianliu, YAN Zihang, WU Jinjin, CHEN Hao, CHEN Lijun, CHEN Yiwei, FU Lijun. Analysis of clinical and genetic characteristics of 18 pediatric patients with Barth syndrome [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(11): 1406-1413.
[9]	WANG Guangpu, WANG Yakun, WU Di, BAI Shoujun. A case of exertional rhabdomyolysis with RYR1 gene variation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(10): 1330-1334.
[10]	DU Zhishan, WANG Yue, SHI Ziyang, SHI Qing, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile and prognostic analysis of thyroid diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(1): 64-71.
[11]	YANG Jingxiao, JIA Ziyao, WU Wenguang, WU Xiangsong, ZHANG Fei, LI Huaifeng, ZHU Yidi, LI Maolan. Effect of BRCA1 R1325K mutation on proliferation and apoptosis of gallbladder cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1071-1079.
[12]	WANG Jinghui, ZHANG Hong, ZHANG Rong, PENG Danfeng, YU Hairong, CHEN Xianghui, XUAN Ye, HU Cheng, GU Yunjuan. Screening for pathogenic variants in obese cohort using whole-exome sequencing [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 882-889.
[13]	MENG Xiangyu, YAN Dandan, CHEN Xianghui, LAI Siyu, XU Yun, GENG Ruina, ZHANG Hong, ZHANG Rong, HU Cheng, YAN Jing. Identification of pathogenic mutations for a Wolfram syndrome pedigree by whole exome sequencing and analysis of its clinical characteristics [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 898-905.
[14]	YIN Zi, LIAN Chaoyang, GAO Bo, TIAN Ying, HAO Qian, YEAP Lengsiew. Enhancement of the neutralization ability resulting from a single amino acid change in the light chain of a chimeric antibody against SARS-CoV-2 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 718-727.
[15]	HUANG Huayan, XU-ZHANG Wendi, XIA Liliang, YU Yongfeng, LU Shun. Advances in immunotherapy of advanced non-small cell lung cancer with EGFR mutation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 611-618.